Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Prostate Cancer

  Free Subscription


17.08.2026

1 Am J Clin Pathol
7 BJU Int
2 BMC Urol
1 Cancer
1 Cancer Lett
1 Cancer Res
1 Clin Cancer Res
2 Eur J Radiol
1 Eur Radiol
3 Eur Urol
1 Int J Cancer
1 Int J Radiat Oncol Biol Phys
4 Int J Urol
1 J Magn Reson Imaging
3 J Nucl Med
1 J Urol
4 JAMA
1 Mod Pathol
3 Prostate
1 Urol Int


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Clin Pathol

  1. IAKYMENKO OA, Khosravaniardakani S, Menendez A, Sioni SR, et al
    Risk factors for lymph node metastasis in a contemporary radical prostatectomy cohort.
    Am J Clin Pathol. 2026;166:aqag095.
    PubMed         Abstract available


    BJU Int

  2. YANG X, He Z, Chen J, Lei H, et al
    Evaluation of triplet therapy combined with robot-assisted cytoreductive prostatectomy for high-volume metastatic prostate cancer: a multicentre randomised controlled trial protocol.
    BJU Int. 2026 Aug 14. doi: 10.1111/bju.70421.
    PubMed         Abstract available

  3. BASKIN AS, Hoffman KE, Penson DF, Huang LC, et al
    Long-term oncological outcomes from a prospective cohort of patients with localised prostate cancer.
    BJU Int. 2026 Aug 12. doi: 10.1111/bju.70410.
    PubMed         Abstract available

  4. WEI C, Wei Q, Qiu S
    Why immunotherapy fails in prostate cancer and what comes next.
    BJU Int. 2026 Aug 12. doi: 10.1111/bju.70427.
    PubMed        

  5. STABILE A, Brancaccio M, Scilipoti P, Barletta FM, et al
    Patient selection for prostate cancer focal therapy guided by mpMRI-PSMA PET concordance and pathology review.
    BJU Int. 2026 Aug 11. doi: 10.1111/bju.70420.
    PubMed        

  6. GIUDICI N, Scuderi S, Palsdottir T, Nordstrom T, et al
    STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.
    BJU Int. 2026;138:471-479.
    PubMed         Abstract available

  7. ROESSLER N, Nowicka Z, Miszczyk M, Calleris G, et al
    Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy.
    BJU Int. 2026;138:430-437.
    PubMed         Abstract available

  8. SOPUTRO NA, Rais-Bahrami S, Bjurlin M, Srivastava A, et al
    International Delphi consensus on single-port robotic radical prostatectomy: patient selection, surgical technique, and training.
    BJU Int. 2026;138:456-463.
    PubMed         Abstract available


    BMC Urol

  9. IRUSEN H, Fernandez P, Esterhuizen T, van der Merwe A, et al
    Depression, anxiety, and health related quality of life following radical prostatectomy and radiation treatment: 12 month outcomes in a South African cohort.
    BMC Urol. 2026;26:191.
    PubMed         Abstract available

  10. AYKANAT IC, Muduroglu M, Mese SK, Ozkan A, et al
    AirSeal((R)) versus conventional insufflation in robot-assisted radical prostatectomy: effects on operative efficiency, pain, and perioperative outcomes.
    BMC Urol. 2026;26:194.
    PubMed         Abstract available


    Cancer

  11. FREEDLAND SJ, Gao W, Touya M, Yang H, et al
    How low do you need to go? Association between various prostate-specific antigen response measures and clinical outcomes in metastatic castration-sensitive prostate cancer in the Veterans Health Administration data.
    Cancer. 2026;132:e70494.
    PubMed         Abstract available


    Cancer Lett

  12. LONG J, Lin Y, Chen Y, Gao M, et al
    Lactylation of EIF4A3 mediates sustained circPTK2 biogenesis to drive prostate cancer metastasis.
    Cancer Lett. 2026 Aug 13:218783. doi: 10.1016/j.canlet.2026.218783.
    PubMed         Abstract available


    Cancer Res

  13. OWEN KL, Gearing LJ, Niranjan B, Jayawardana M, et al
    Spatial Profiling Reveals Immune Escape Pathways and Therapeutic Vulnerabilities in Prostate Cancer Bone Metastases.
    Cancer Res. 2026 Aug 11. doi: 10.1158/0008-5472.CAN-26-2386.
    PubMed         Abstract available


    Clin Cancer Res

  14. BLINKA S, Arora S, Rudoy D, Gowda A, et al
    SPEN inactivation drives resistance to androgen receptor pathway inhibitors in metastatic prostate cancer.
    Clin Cancer Res. 2026 Aug 13. doi: 10.1158/1078-0432.CCR-26-1405.
    PubMed         Abstract available


    Eur J Radiol

  15. LEE YJ, Choi MH, Kim H, Jeong G, et al
    Vendor-neutral deep learning reconstruction of dynamic contrast-enhanced prostate MRI: Image quality improvement and preservation of diagnostic performance.
    Eur J Radiol. 2026;203:113020.
    PubMed         Abstract available

  16. COELHO FMA, Mussi TC, Moreira LF, Vilas Boas IP, et al
    Limited reproducibility of PI-RADS v2.1 upgrading rule subcategorization in MRI-visible peripheral zone lesions: A lesion-level targeted-biopsy study.
    Eur J Radiol. 2026;203:113004.
    PubMed         Abstract available


    Eur Radiol

  17. D'ERME L, Avesani G, Russo L, Bottazzi S, et al
    Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.
    Eur Radiol. 2026 Aug 13. doi: 10.1007/s00330-026-12792.
    PubMed         Abstract available


    Eur Urol

  18. QUARTA L, Zaurito P, Viti A, Cosenza A, et al
    PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.
    Eur Urol. 2026 Aug 11:S0302-2838(26)02314-6. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available

  19. SAAD F, Shore N, Vjaters E, Olmos D, et al
    Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.
    Eur Urol. 2026 Aug 12:S0302-2838(26)02313-4. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available

  20. RANNIKKO AS, Kilpelainen TP, Auvinen A
    Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.
    Eur Urol. 2026 Aug 12:S0302-2838(26)02316-X. doi: 10.1016/j.eururo.2026.
    PubMed         Abstract available


    Int J Cancer

  21. VICKERS AJ, Kasivisvanathan V, Brentnall AR
    Effect of Implementing Population-Based Prostate-Specific Antigen Screening on Testing Rates and Prostate Cancer Overdiagnosis in England: A Statistical Modelling Study.
    Int J Cancer. 2026 Aug 9. doi: 10.1002/ijc.70698.
    PubMed         Abstract available


    Int J Radiat Oncol Biol Phys

  22. VIAL N, Dess RT, Zilli T
    Beyond the "Swan Song": Salvage Stereotactic Body Radiation Therapy for Nodal Oligorecurrence in Previously Irradiated Prostate Cancer - Lessons From the CYGNUS Retrospective Study.
    Int J Radiat Oncol Biol Phys. 2026;126:193-195.
    PubMed        


    Int J Urol

  23. OONO T, Terashita M, Mori S, Oka A, et al
    Validation of the NCCN Subclassification for Intermediate-Risk Prostate Cancer in a Japanese Radical Prostatectomy Cohort: Results From the MICAN Study.
    Int J Urol. 2026;33:e70592.
    PubMed         Abstract available

  24. SUGIHARA N, Sawada T, Arai H, Nishida K, et al
    Clinical Outcomes of Single-Dose Flomoxef Prophylaxis for Transrectal Prostate Biopsy: A Single-Center Study of 834 Cases.
    Int J Urol. 2026;33:e70595.
    PubMed         Abstract available

  25. NAKAI Y
    Editorial Comment on "Prognostic Impact and Metastasis Propensity of Grade Group 5 Prostate Cancer Following Permanent Seed Implantation Brachytherapy-Based Trimodality Therapy: Implications for Intensified Staging and Systemic Therapy Optimization".
    Int J Urol. 2026;33:e70605.
    PubMed        

  26. KAMIYAMA M, Izumi K, Mitsui T, Shima T, et al
    Sequential Enzalutamide-Docetaxel Versus Abiraterone-Docetaxel Therapy in Castration-Resistant Prostate Cancer: A Subanalysis of the ENABLE Study.
    Int J Urol. 2026;33:e70599.
    PubMed         Abstract available


    J Magn Reson Imaging

  27. KIM D, Pabi R, Borisch EA, Froemming AT, et al
    Optimal Selection of the Effective Echo Time (TE(eff)) for T2-Weighted Fast-Spin-Echo MRI of the Prostate at 3.0 T: Effect on Lesion Conspicuity.
    J Magn Reson Imaging. 2026 Apr 23. doi: 10.1002/jmri.70351.
    PubMed         Abstract available


    J Nucl Med

  28. BEKKHOUCHA A, Zaragori T, Olivier P, Claudin M, et al
    Prognostic Value of [(18)F]FDG PET Combined with [(68)Ga]Ga-PSMA PET as Pretreatment Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with [(177)Lu]Lu-PSMA-617.
    J Nucl Med. 2026 Aug 13:jnumed.126.273113. doi: 10.2967/jnumed.126.273113.
    PubMed         Abstract available

  29. IRAVANI A, Gulati R, Miyaoka R, Reiger AC, et al
    Clinical Trial Protocol for LPS-Boost: Intensified [(177)Lu]Lu-PSMA-617 Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer with Low PSMA-Expressing Disease.
    J Nucl Med. 2026 Aug 13:jnumed.126.272472. doi: 10.2967/jnumed.126.272472.
    PubMed         Abstract available

  30. PARK HL, Kersting D, Bergstrom CP, Khaki AR, et al
    Association of Early Same-Day Posttherapy Whole-Body SPECT/CT Using Visual RECIP 1.0 with Overall Survival During [(177)Lu]Lu-PSMA-617 Therapy for Metastatic Castration-Resistant Prostate Cancer.
    J Nucl Med. 2026 Aug 13:jnumed.126.272651. doi: 10.2967/jnumed.126.272651.
    PubMed         Abstract available


    J Urol

  31. GUHA A, Terris M
    Cardiovascular Disease: The Missing Recommendation in the 2026 AUA/SUO Advanced Prostate Cancer Guideline.
    J Urol. 2026 Aug 11:101097JU0000000000005238. doi: 10.1097/JU.0000000000005238.
    PubMed        


    JAMA

  32. LEE G, Bihn JR, Culnan JM, La J, et al
    Active Surveillance Use for Favorable-Risk Prostate Cancer in a Veterans Affairs Population.
    JAMA. 2026 Aug 13. doi: 10.1001/jama.2026.13471.
    PubMed        

  33. COSENZA A, Nguyen DD, Qian Z, Bernardino R, et al
    Focal Therapy for Prostate Cancer.
    JAMA. 2026 Aug 13. doi: 10.1001/jama.2026.12411.
    PubMed        


  34. Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: Research Summary.
    JAMA. 2026 Aug 13:e2612679. doi: 10.1001/jama.2026.12679.
    PubMed        

  35. ELLIS RJ, Pugh SL, Yu JB, Feng FY, et al
    Stereotactic Body Radiotherapy vs Moderately Hypofractionated IMRT for Localized Intermediate-Risk Prostate Cancer: A Randomized Clinical Trial.
    JAMA. 2026 Aug 13. doi: 10.1001/jama.2026.12627.
    PubMed         Abstract available


    Mod Pathol

  36. SFANOS KS, Morton R, Flores JN, Sosa RY, et al
    Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.
    Mod Pathol. 2026 Aug 12:101065. doi: 10.1016/j.modpat.2026.101065.
    PubMed         Abstract available


    Prostate

  37. HASHIMOTO K, Izumi K, Shima T, Kato Y, et al
    The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.
    Prostate. 2026;86:1322-1331.
    PubMed         Abstract available

  38. AOYAGI C, Aso S, Tachibana M, Gunge N, et al
    Association Between Intraoperative Prostate Bed Blood Flow and Postoperative Lower Urinary Tract Symptoms After Robot-Assisted Radical Prostatectomy.
    Prostate. 2026;86:1367-1374.
    PubMed         Abstract available

  39. GOMEZ-LUQUE MA, De Pablos-Rodriguez P, Perez-Fentes DA, Picola-Brau N, et al
    Clinical Variable-Based Machine Learning for Predicting Early mCRPC Using Exclusively Clinical Variables: Development and Multicenter External Validation.
    Prostate. 2026;86:1352-1366.
    PubMed         Abstract available


    Urol Int

  40. STEENBOCK O, Rieger C, Heidenreich J, Paffenholz P, et al
    How Often are druggable mutations detectable in Metastatic Castration Resistant Prostate Cancer?
    Urol Int. 2026 Aug 13:1. doi: 10.1159.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum